A genetic variant that is considered the most powerful risk factor for developing the disease Alzheimer’s Late onset is also associated with an increased risk of developing subclinical (asymptomatic) atherosclerosis.
It has been verified by a team of scientists from the National Cardiovascular Research Center (CNIC) in Madrid (Spain) coordinated by Marta Cortes Canteli and Valentin Fuster -director of the center-, and the results have been published today in the journal Circulation Research.
Researchers have proven that a gene – that of “apolipoprotein E4” or APOE4 -, associated with the risk of developing Alzheimer’s, is also behind subclinical atherosclerosis, but also that people who carry a variant of that gene (the “APOE2 ″) are protected against both diseases.
The results of this research clarify the role of this genetic variant in the development of cardiovascular diseases and have important therapeutic and preventive implications for cardiovascular healthespecially during the first half of adult life, the CNIC stressed in a note released today.
This gene has three alleles (versions), and having inherited one or the other gives people a different risk of developing different diseases, including cardiovascular diseases and Alzheimer’s, explained scientist Marta Cortes Canteli, neuroscientist at the CNIC and researcher at the Institute of Jimenez Diaz Foundation Health Research.
People who inherit one allele (APOE4) have high cholesterol levels and a consequent higher risk of suffering from atherosclerosis.while those who have “APOE2″ have less cholesterol and therefore a lower prevalence of suffering from this disease.
The mechanisms responsible for these associations are, however, very complex and the impact of age, sex and other cardiovascular risk factors was not clear until now, particularly in the initial stages of the development of the disease, this center stated. research, dependent on the Carlos III Health Institute (Ministry of Science, Innovation and Universities).
The CNIC researchers corroborated in middle-aged individuals who are included in the PESA-CNIC-Santander study (aged between 40 and 54 years) that there is an increased risk of developing subclinical atherosclerosis among people who have elevated LDL levels cholesterol (the “bad” cholesterol), which opens a possible way to implement early intervention strategies.
“All of this highlights, once again, the importance of maintaining a healthy lifestyle,” said CNIC director Valentin Fuster, president of the Cardiovascular Institute and chief physician at Mount Sinai Medical Center in New York.
The results of this research suggest that knowing the genetic variant that is present in each individual could improve the classification of cardiovascular risk, “especially during the initial stages of the development of cardiovascular disease”highlighted researcher Catarina Tristão Pereira, first signatory of the article.
The PESA-CNIC-Santander is a prospective study that includes more than 4,000 asymptomatic middle-aged participants in whom the presence and development of subclinical atherosclerosis has been exhaustively evaluated since 2010.
This study was financed by the European Regional Development Fund (ERDF) and the European Social Fund (ESF), and researchers from the Network Biomedical Research Center for Cardiovascular Diseases (CiberCV) and the CIBER for Rare Diseases participated in it ( CiberRER).
